Introduction Primary subclavian vein thrombosis (PSVT) is a rare (incidence 2/100,000) disease affecting predominantly young and physically active persons. A treatment protocol advocated by several studies includes catheter directed thrombolysis (CDT) within 14 days followed by decompressive surgery (TOD). A main purpose of this treatment is to prevent long term complications in form of Post-Thrombotic Syndrome (PTS), which manifests as reduced quality of life (QoL), assessed by the Disability of the Arm, Shoulder and Hand (DASH) score. CDT is rarely successful if started later than 14 days after the onset of symptoms. However, it is not known how a delay within the timespan of two weeks affects QoL in PSVT patients.

Aims To investigate if there is a significant difference in QoL between PSVT patients receiving early treatment with CDT compared to those receiving delayed CDT.

Material and Methods DASH score from 65 PSVT patients in Stockholm 2006-2018 was evaluated pretreatment and at one year follow up. Patients were divided into two groups depending on time from symptom to treatment with CDT. Early treatment group (0-3 days to CDT) was compared to delayed treatment group (4-14 days to CDT). Chi2 test was used to analyze differences in patient characteristics and Mann-Whitney-U test was used to identify any differences between the groups.

Results No significant differences were detected (p=0.497)

Conclusions No indication that treatment within 3 days from PSVT symptom onset is superior to treatment after 4-14 days was found. Because of the non-randomized design and small population, further studies are needed.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Regional Ethics Committe of Stockholm County (Regionala Etikprovningsnaemnden i Stockholm) gave ethical approval for this work (Diary number 2016/2484-31/2)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Individual participant data underlying the results reported in this Article will be made available after de-identification, alongside a data dictionary, study protocol, and informed consent form. The data will be available at Article publication and for 10 years subsequently. Data will be shared for individual participant data meta-analysis with other members of the research community who have an affiliation to a recognised medical university. Data will only be shared with investigator support and after approval of a proposal, and with a signed data access agreement. Additional restrictions apply according to Swedish law.